Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS

Authors

Jonathan Marshall
Dave Singh
Mona Bafadhel (ORCID: https://orcid.org/0000-0002-9993-2478)
Himanshu Parikh (ORCID: https://orcid.org/0000-0002-1755-2130)
Mehul Patel (ORCID: https://orcid.org/0000-0002-2304-3324)
Charlotta Movitz
Dobrawa Kisielewicz
Niki Arya
Karin Bowen

Institutions

King's College London (GB)
AstraZeneca (France) (FR)
AstraZeneca (Switzerland) (CH)
AstraZeneca (Poland) (PL)
AstraZeneca (Finland) (FI)
AstraZeneca (Italy) (IT)
AstraZeneca (Spain) (ES)

Publication Details

Journal: Respiratory Research
Published: 2025-05-08
DOI: https://doi.org/10.1186/s12931-025-03234-5
Citations: 2
Primary Topic: Chronic Obstructive Pulmonary Disease (COPD) Research
Type: article
Field-Weighted Citation Impact: 3.04

Funders

AstraZeneca
National Institute for Health and Care Research
Manchester Biomedical Research Centre

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS

Jonathan Marshall, Dave Singh, Mona Bafadhel, Himanshu Parikh et al.

May 8, 2025

2 citations

Respiratory Research

Chronic Obstructive Pulmonary Disease (COPD) Research

3.04

article

Step up to triple therapy versus switch to dual bronchodilator therapy in patients with COPD on an inhaled corticosteroid/long-acting β2-agonist: post-hoc analyses of KRONOS

Jonathan Marshall, Dave Singh, Mona Bafadhel, Himanshu Parikh, Mehul Patel, Charlotta Movitz, Dobrawa Kisielewicz, Niki Arya, Karin Bowen

May 8, 2025article en

2 citations

Abstract

No abstract available for this paper.

Respiratory ResearchVol. 26(1)

King's College London (GB), AstraZeneca (France) (FR), AstraZeneca (Switzerland) (CH), AstraZeneca (Poland) (PL), AstraZeneca (Finland) (FI), AstraZeneca (Italy) (IT), AstraZeneca (Spain) (ES)

AstraZeneca, National Institute for Health and Care Research, Manchester Biomedical Research Centre

Openalex Percentile: Top 10%

Chronic Obstructive Pulmonary Disease (COPD) Research

3.04

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.